YS247

· Peking University Third Hospital

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for YS247, covering 2026-03-16 to 2026-03-16. Get the full timeline:

Most recent: Clinical Trial Update: A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer [NA]

See pricing